SynthesisOncology2026
Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review.
Synthesis in Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review.Oncology · 2026Pooled it
- Tyrosine Kinase Inhibitor Treatment of a Patient with Chronic Myeloid Leukemia and Congenital Thrombophilia.Hematology reports · 2025Article
- Do We Need A CML-Specific Bleeding Tool? Concerns About The Proposed BAT-CML.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: The prognosis of chronic myeloid leukemia (CML) has been revolutionized in recent decades with tyrosine kinase inhibitors (TKIs). Yet, comorbidities that require anticoagulation therapy pose a challenge in CML management because of the scarcity of evidence on the optimal drug combinations. This systematic review (SR) aimed to summarize the efficacy and safety considerations for the concomitant use of anticoagulants with different TKIs in CML and investigate their potential drug interactions.
methodsA comprehensive search strategy was used, employing Medical Subject Headings and free-text terms across databases including PubMed (via OVID), Medline (via OVID), Embase (via OVID), and Web of Science. Members of the research team independently screened the titles and abstracts for eligibility based on predefined inclusion and exclusion criteria. Data extraction was then performed using a standardized form to record the studies' characteristics, the TKIs and anticoagulants used, and the safety outcomes. Two reviewers independently assessed study quality using the Critical Appraisal Skills Program (CASP) checklists and the Joanna Briggs Institute (JBI) tool for case reports.
resultsThe search yielded 406 studies, of which 13 met the inclusion criteria for reporting real-world safety data in adults receiving TKIs with anticoagulants. Overall, the combinations of TKIs with anticoagulants like ponatinib with apixaban and imatinib with warfarin had no major bleeding complications. The pharmacokinetic findings suggested some interaction variability, particularly between nilotinib and warfarin, but overall anticoagulant use appeared safe in the studied populations across various indications.
conclusionThis is the first SR to address a critical gap in the literature by evaluating the safety profiles of various TKIs in combination with different anticoagulants. The findings from cohort studies highlighted the feasibility of concomitant use of anticoagulants and TKIs in CML patients, with close monitoring of potential adverse events and drug interactions. PROSPERO registration number was CRD42024528737. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.